Introduction {#Sec1}
============

Quality of life (QoL) has become an increasingly important outcome in child mental health clinical research \[[@CR10], [@CR11], [@CR14]\], and it has long been recognised that a diagnosis of attention deficit hyperactivity disorder (ADHD) can result in broad impairments of QoL in patients and their families \[[@CR24], [@CR26]\]. QoL in ADHD is influenced by numerous factors \[[@CR35]\], including physical, psychological, cognitive and social aspects of wellbeing and function \[[@CR14]\].

ADHD can have a significant impact on a patient's perception of their QoL. Everyday activities such as school and homework, family routines and playing with other children may be affected, as well as relationships with family members and peers \[[@CR12]\]. QoL in patients with ADHD has been shown to be considerably lower than community norms \[[@CR34]\], and studies show that patients with ADHD experience QoL deficits comparable with those in other chronic diseases, such as asthma, cancer and cerebral palsy \[[@CR17], [@CR38]\]. ADHD has also been shown to impact negatively on parents' QoL and emotional health, and presents a burden on the family as a whole \[[@CR12]\]. Difficulties that families of children with ADHD may experience include strained family relationships, parenting distress and worry, depression, higher incidences of divorce and separation, and possible effects on work status and productivity \[[@CR12], [@CR22]\].

Improvement of patient QoL is regarded as an important treatment goal \[[@CR7]\]. It is thought that treatments that can provide effective symptom control in ADHD may also have the potential to improve patients' overall QoL \[[@CR4]\]. Methylphenidate (MPH) is recognised as the first-line choice of medication for reducing ADHD symptoms in children and adolescents \[[@CR4]\]. However, the effect of MPH treatment on the everyday functioning and wellbeing of children and adolescents with ADHD has not been well studied to date. An open-label study showed that QoL scores improved along with symptoms during 3-month MPH therapy, suggesting that such effects could be secondary to effects on the core features of ADHD \[[@CR21]\]. Consistent with this, a study that had an open-label dose optimisation phase followed by a randomised, placebo-controlled, double-blind classroom phase demonstrated that MPH therapy was associated with a robust improvement in child and family health-related QoL \[[@CR27]\]. Further analyses of the study showed that the improvement in QoL was linked to improvements in both ADHD symptoms and medication satisfaction, with patient satisfaction as a strong predictor of initial changes in QoL as symptom improvement \[[@CR18]\]. There is also some evidence from this and another study that family QoL measures are improved by MPH treatment \[[@CR7], [@CR18]\]. The development of specialised tools (for example the Global Impression of Perceived Difficulties \[GIPD\] scale, the Life Participation Scale \[LPS\] and the Kinder Lebensqualitätsfragebogen \[KINDL\] questionnaire \[[@CR31], [@CR37], [@CR39]\]) allows the opportunity to measure the QoL of children and adolescents with ADHD, and their response to treatment, comprehensively.

Treatment satisfaction and patient/parent preference are increasingly important determinants of the success of clinical care in ADHD \[[@CR20]\]. Improved patient satisfaction may result in better outcomes through greater adherence to therapy \[[@CR8]\]. Parents are often asked how satisfied they are with ADHD medication in clinical trials \[[@CR5]\], and generally show higher rates of satisfaction than their children, particularly in the treatment of ADHD \[[@CR16]\]. Multiple dosing can be problematic, as it can cause adherence issues and complications related to privacy, stigmatisation by classmates, potential abuse and accountability of the school administration \[[@CR23]\]. By eliminating the need for multiple daily dosing, the introduction of once-daily, long-acting medication has improved the convenience of ADHD treatment, with potential for greater satisfaction for both patients and their parents.

The OBSEER (OBservation of Safety and Effectiveness of Equasym XL^®^ in Routine care) study was an observational, non-controlled, non-interventional, post-marketing surveillance study conducted in Germany, which examined changes in effectiveness and safety outcomes over 3 months in patients with ADHD receiving once-daily Equasym XL^®^[1](#Fn1){ref-type="fn"} (Shire Pharmaceuticals Ireland Limited, Ireland) \[[@CR15]\]. In this paper, we present a longitudinal assessment of QoL and medication satisfaction, including adherence and tolerability, in patients enrolled in the OBSEER study.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The open-label, prospective, multicentre, observational, post-marketing OBSEER study was designed primarily to assess the effectiveness and safety, and is described in full elsewhere \[[@CR15]\]. Here, pre-specified outcomes related to QoL and satisfaction with therapy are examined.

Patients and treatment {#Sec4}
----------------------

Patients with ADHD (diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision \[DSM\]-IV-TR \[[@CR2]\] or the International Classification of Diseases \[ICD\]-10 criteria \[[@CR40]\]) aged 6--17 years and attending school were included if treatment with Equasym XL^®^ was planned by the treating physician. Patients were included whether or not they had received Equasym XL^®^ or other treatment prior to the study.

Treatment with once-daily Equasym XL^®^ was administered according to standard practice under the therapeutic responsibility of the attending physician; ethics or institutional review board approval was not required for this study. Written informed consent was obtained from parents.

Assessments {#Sec5}
-----------

### Health-related QoL {#Sec6}

QoL was assessed using the KINDL questionnaire for the assessment of health-related QoL in childhood and adolescence \[[@CR31]\]. This is a short, validated tool comprising 24 items, with six subscores (*physical wellbeing, emotional wellbeing, self*-*esteem, family, friends* and *school*). Three different versions were used according to the age group: KID-KINDL was used for children aged 6--11 years old; the self-reported KIDDO-KINDL for adolescents aged 12--17 years old; and KINDL for parents of patients aged 6--17 years old. Scores were transformed such that the range of possible values for the sub-scores and the total score was from 0 (most negative state) to 100 (most positive state).

### Treatment satisfaction {#Sec7}

Treatment satisfaction was evaluated using the Satisfaction with Medication scale (SAMS), a newly designed tool that consists of 12 items (including an item for global satisfaction with medication) scored on a six-point scale, with low values indicating positive attitudes to drug therapy, and high values indicating negative attitudes. The parent report form of the SAMS (SAMS-P) assessed parents' satisfaction with medication, while the self-report form (SAMS-S) assessed patient satisfaction with medication. The total score of each rating scale is the sum of the item divided by the number of items, and ranged from 1 to 6. The development of the SAMS tool is described in a companion paper \[[@CR20]\].

### Physician-rated adherence and tolerability {#Sec8}

Adherence to treatment was graded on a scale between 1 and 6 (where 1 = excellent \[very good\] and 6 = failed \[inadequate\]) by the treating physician. Treatment tolerability was assessed by the treating physician as 'very good', 'good', 'moderate' and or 'poor'.

### Assessment timings {#Sec9}

The planned observation period for each patient was 6--12 weeks after first use of Equasym XL^®^. Three visits were planned: Visit 1, baseline visit and initiation of Equasym XL^®^ treatment; Visit 2, follow-up visit scheduled for 1--3 weeks after first use of Equasym XL^®^; Visit 3, final visit 6--12 weeks after first use of Equasym XL^®^. The attending physician assessed adherence at each visit, and global tolerability at Visit 3. Patients and parents assessed satisfaction with medication at each visit, and QoL at Visit 1 and Visit 3.

Statistical analyses {#Sec10}
--------------------

The following outcomes were assessed: parent-rated satisfaction with therapy and perception of patient's QoL by visit and as change from baseline; patient-rated satisfaction with therapy and QoL by visit and as change from baseline; physician-rated tolerability and adherence.

Results presented are for the intent-to-treat population. All statistical analyses were performed post-hoc. Paired *t* tests were used for the analyses of KINDL scores, and multivariate analysis of variance for the analyses of SAMS scores; effect sizes \[[@CR28], [@CR36]\] were calculated using Cohen's *d* \[[@CR13]\]. In subgroup analyses, patients were assigned to groups according to their treatment prior to starting Equasym XL^®^ (no treatment; or treatment with MPH modified release (MR), MPH immediate release (IR) administered once daily, MPH-IR administered several times per day, or 'other', where treatment was unspecified (atomoxetine, amphetamine or insufficiently specified).

Results {#Sec11}
=======

Study population {#Sec12}
----------------

In total, 852 patients were registered for the study. Thirty patients were excluded from the analysis due to invalid data; therefore, 822 patients were included in the safety analysis population. Baseline demographics for the total population are described elsewhere \[[@CR15]\].

Six hundred and fourteen patients had received prior treatment for ADHD, while 208 patients were treatment-naïve; baseline characteristics by prior treatment group are shown in Table [1](#Tab1){ref-type="table"}. The mean (standard deviation \[SD\]) timing for Visit 3 was 10.1 (4.0) weeks after the first use of Equasym XL^®^.Table 1Baseline demographics and disease characteristics by prior treatment*N*NoneMPH-IR once-dailyMPH-IR repeatedMPH-MROther, no specificationBaseline demographics (*n* = 822) Patients, *n* (%)822208 (25.30)101 (12.29)270 (32.84)203 (24.70)40 (4.87) Male, *n* (%)663167 (25.19)80 (12.07)217 (32.73)166 (25.04)33 (4.98) Mean (SD) age (years)8089.76 (2.74)9.78 (2.25)9.94 (2.40)10.46 (2.29)10.61 (2.60) Mean (SD) height (cm)764143.15 (15.62)143.30 (14.77)142.81 (14.52)145.73 (15.58)144.22 (14.51) Mean (SD) weight (kg)78638.32 (14.82)37.34 (12.28)37.79 (13.90)38.37 (12.85)37.10 (12.34) Mean (SD) BMI (kg/m^2^)75818.13 (3.56)17.74 (3.13)18.01 (3.62)17.71 (3.17)17.47 (3.04)ADHD diagnosis (*n* = 778) F90.0: disturbance of activity/attention, *n* (%)431100 (52.08)47 (52.22)152 (57.58)116 (58.88)16 (45.71) F90.1: hyperkinetic conduct disorder, *n* (%)28369 (35.94)32 (35.56)94 (35.61)71 (36.04)17 (48.57) F90.8: other hyperkinetic disorders, *n* (%)6423 (11.98)11 (12.22)18 (6.82)10 (5.08)2 (5.71)*BMI*body mass index,*IR* immediate release,*MR*modified release,*MPH*methylphenidate,*SD* standard deviation

Health-related quality of life {#Sec13}
------------------------------

On an average, the parent-rated KINDL total score was 62.8 points at Visit 1 and 71.1 points at Visit 3, indicating a 13.3% improvement in QoL on treatment with Equasym XL^®^, which was significant (*p* \< 0.001; Table [2](#Tab2){ref-type="table"}). Descriptively, the greatest improvement was for the sub-score *school*, which increased by 11.1 points, and the smallest improvement was for the sub-score *physical wellbeing*, which increased by 6.9 points. Similarly, the patient-rated KID-KINDL (6--11 years) total score averaged 66.3 points at Visit 1 and 73.4 points at Visit 3, indicating an improvement in QoL across all subscales with Equasym XL^®^ which was significant (*p* \< 0.001; Table [2](#Tab2){ref-type="table"}). The greatest improvement in the KID-KINDL was for *school*, which increased by 11.1 points, while the smallest improvement was for *physical wellbeing*, which increased by 4.9 points. Effect sizes of parent ratings (Cohen's *d* = 0.37--0.67) and patient ratings (Cohen's *d* = 0.22--0.54) were all in the small-to-moderate range (Table [2](#Tab2){ref-type="table"}).Table 2Summary of analysis of KINDL quality of life scores (on three different versions of the questionnaire) for patients and their parentsQuality of life rating scale*N*Assessment visitMain effect *t* test and effect sizeVisit 1Visit 3*t*\*Cohen's *d* (Visit 1--Visit 3)Mean (SD)Mean (SD)Parent ratings (KINDL-P) Total score59062.75 (13.34)71.10 (11.71)−16.30.67 Physical wellbeing60071.83 (18.25)78.77 (16.35)−9.10.37 Emotional wellbeing60067.55 (17.52)74.77 (15.08)−10.30.42 Self esteem60054.94 (18.26)63.50 (16.26)−11.60.47 Family60062.06 (19.42)69.42 (16.90)−10.20.42 Friends60060.19 (20.99)68.74 (17.85)−11.30.46 School59060.67 (18.56)71.81 (16.28)−14.40.59Patient ratings (age 6--11 years, KID-KINDL) Total score43866.28 (13.37)73.38 (11.66)−10.90.52 Physical wellbeing44574.08 (17.15)78.93 (16.44)−5.40.26 Emotional wellbeing44571.66 (16.77)77.02 (14.68)−6.40.30 Self esteem44558.10 (20.11)65.88 (19.88)−7.40.35 Family44467.43 (20.12)75.02 (16.05)−8.30.39 Friends44466.85 (21.49)73.02 (18.91)−6.30.30 School44059.15 (22.01)70.24 (18.06)−10.20.48Patient ratings (age 12--17 years, KIDDO-KINDL) Total score15265.63 (12.88)71.69 (12.20)−6.20.51 Physical wellbeing15472.81 (17.54)77.68 (16.45)−3.40.28 Emotional wellbeing15472.40 (16.18)76.18 (14.85)−2.80.22 Self esteem15457.36 (18.78)64.77 (18.90)−5.10.41 Family15466.25 (23.18)73.17 (19.05)−4.20.34 Friends15468.14 (19.99)72.63 (17.41)−3.20.25 School15255.98 (16.45)65.21 (16.33)−6.70.54Cohen's *d* effect sizes are considered small (0.20 ≥ *d* \< 0.50), medium (0.50 ≥ *d* \< 0.80) or large (0.80 ≥ *d*) \[[@CR13]\]*SD* standard deviation\* All effects are statistically significant at *p* \< 0.001

There were no substantial differences between the results of the KID-KINDL questionnaire and the KIDDO-KINDL (12--17 years) version for the total score (*t* = 0.350; *p* = 0.726) and all other scores (Table [2](#Tab2){ref-type="table"}). The KIDDO-KINDL total score averaged 65.6 at Visit 1 and 71.7 at Visit 3, which was a significant improvement (*p* \< 0.001; Table [2](#Tab2){ref-type="table"}). In analyses by prior treatment, improvements were found in all subgroups, with the largest effects for both parents' and patients' ratings seen in the group with no prior pharmacotherapy (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Quality of life total scores (KINDL questionnaire, parent ratings) during the study, by prior treatment. All comparisons are significant at *p* ≤ 0.001 (two-tailed test between KINDL total score at Visit 1 versus total score at Visit 3). *IR* immediate release, *MPH* methylphenidate, *MR* modified release

Treatment satisfaction {#Sec14}
----------------------

For patients with at least one post-baseline visit, both parent- and patient-rated SAMS scores decreased from Visit 1 to the last visit (Visit 2 or Visit 3), indicating an improvement in satisfaction on medication with Equasym XL^®^ compared with previous drug therapy (Table [3](#Tab3){ref-type="table"}). Mean (SD) scores decreased from 2.8 (1.1) to 2.4 (1.1) points for parent ratings, and from 2.6 (1.0) to 2.3 (1.0) points for patient ratings. Thus, both patients and their parents rated therapy with Equasym XL^®^ as better than the previous drug therapy.Table 3Summary of analysis of satisfaction with medication scale scores for patients and their parentsSatisfaction with medication*N*Assessment visitMain effect MANOVA and effect sizeVisit 1Visit 2Visit 3F (t)\*Cohen's *d* (Visit 1--Visit 3)MeanSDMeanSDMeanSDParent rating4842.801.072.551.042.411.0723.20.31Patient rating4682.590.962.340.962.270.9822.50.38*ANOVA* analysis of variance;*SD* standard deviation\* All effects are statistically significant at *p* \< 0.001

Subgroup analyses by prior treatment showed that the smallest improvement in patient satisfaction was found for the group of patients who had been previously treated with MPH-MR (difference in scores −0.13) and the greatest improvement was in the 'other' subgroup (difference in scores −0.70). By parental assessment, improvements over previous MPH treatment were similar for MPH-MR, once-daily MPH-IR and MPH-IR administered several times a day (−0.34, −0.33 and −0.39, respectively) and greatest for the 'Other' subgroup (--0.85).

Physician-rated adherence {#Sec15}
-------------------------

The mean (SD) adherence score improved from 2.1 (1.2) to 1.5 (1.0) during the study, with the majority of patients rated by their physician as 'very good' or 'good' at last visit (Fig. [2](#Fig2){ref-type="fig"}a). Adherence during Equasym XL^®^ treatment was frequently rated as superior to adherence during prior treatment (Fig. [2](#Fig2){ref-type="fig"}b). A particular advantage was noted for Equasym XL^®^ versus MPH-IR administered several times per day, with 57.7% of the patients rated as having better adherence with Equasym XL^®^.Fig. 2**a** Mean ratings of adherence to treatment with Equasym XL^®^, as assessed by attending physicians, at last visit. *n* = 773; 49 missing values. *1* very good, *6* fail. **b** Adherence to treatment with Equasym XL^®^ compared with adherence to prior treatment. *n* = 553; 61 missing values. *IR* immediate release, *MPH* methylphenidate, *MR* modified release

Physician-rated tolerability {#Sec16}
----------------------------

Adverse events are reported elsewhere \[[@CR15]\]. Treatment with Equasym XL^®^ was generally well tolerated; a total of 26/822 evaluable patients (3.2%) discontinued treatment due to adverse events.

At Visit 3, physicians rated the global tolerability of Equasym XL^®^ as 'very good' in the majority (415/734; 56.5%) of the patients. 'Good' was the next most frequent tolerability rating, for 270/734 (36.8%) patients, with only 33/734 (4.5%) patients rated as having 'moderate' tolerability and 16/734 (2.2%) patients as 'poor' (no assessment was provided for 88 patients). When analysed by prior treatment, the main differences were seen in the categories 'very good' and 'good' (Fig. [3](#Fig3){ref-type="fig"}). Patients who were treated with MPH-MR prior to the study showed the highest ratings for the categories 'moderate' and 'poor'.Fig. 3Physician-rated global assessment of tolerability at Visit 3, by prior treatment. *n* = 734; 88 missing values. *IR* immediate release, *MPH* methylphenidate, *MR* modified release

Discussion {#Sec17}
==========

We report that patients with ADHD showed improvements in QoL and satisfaction with medication during treatment with once-daily Equasym XL^®^ in this large observational study. Improvements were similar for both parent- and patient-assessed outcomes. There were no signs that patient tolerability of Equasym XL^®^ differed under routine care conditions compared with the clinical trial setting.

In line with the emerging evidence showing that QoL improves with effective treatment \[[@CR14]\], parents scored total QoL as 13.3% higher and patient-reported total QoL scores were 10.8% higher during Equasym XL^®^ treatment compared with before starting Equasym XL^®^. On both parents' and patients' ratings, QoL improvements during the study were greatest for the subgroup of patients who had not received any prior treatment. Due to the potential for discrepancies between parent and child reports, with parents tending to rate their children with ADHD as having lower QoL than the children themselves \[[@CR14]\], it is generally recommended that both perspectives are assessed to provide a comprehensive assessment \[[@CR10], [@CR25]\]. Poor parent--child agreement in health-related QoL was reported in a recent study \[[@CR30]\], but another study showed improvement in QoL in both children and their families, following a change in MR formulation \[[@CR6]\]. Our observations appear to show a good concordance between patients and their parents in terms of QoL and satisfaction outcomes, which were rated as improved to a similar extent by both groups (although statistical testing was not performed).

There is a general lack of consistency across studies in the instruments that have been used to measure QoL, which, together with variability in how QoL is defined, makes cross-study, and cross-disease, comparisons difficult \[[@CR14]\]. However, the BELLA study also used the KINDL questionnaire to assess QoL \[[@CR32]\]. In that study, the mean (SD) KINDL total score was 76.3 (10.1), as rated by parents of children aged 7--17 years, and 73.0 (10.2) from self-ratings of children and adolescents aged 11--17 years \[[@CR32]\]. Comparison of OBSEER data (Table [2](#Tab2){ref-type="table"}) with this reference population showed that overall QoL approached normative values after treatment with Equasym XL^®^, although it should be noted that this effect was not consistently seen across all subscales, and that age groupings are not directly comparable between the two studies.

According to physicians' assessments, the tolerability of treatment was rated 'very good' or 'good' in 93.3% of the patients. Furthermore, both patients and their parents rated therapy with Equasym XL^®^ as better than the previous drug therapy. Specific reasons for this preference were not investigated; however, it could be hypothesised that a positive clinical response would increase the likelihood of overall patient satisfaction with study treatment. Indeed, adherence generally decreases when there is a limited improvement in symptoms, or if adverse events occur \[[@CR8]\].

Increased satisfaction should also have a positive impact on adherence to therapy. In this study, adherence was generally rated by physicians as 'very good' or 'good', and was frequently rated as better than during prior treatment, particularly for patients who had received MPH-IR dosed several times per day. This supports previous studies showing improved adherence with once-daily formulations versus multiple daily doses of IR formulations \[[@CR29]\]. Improved adherence may result from Equasym XL^®^ meeting patient's daily needs better than conventional MPH preparations, because of factors such as its particular pharmacokinetic profile \[[@CR3]\] or greater ease of administration. Although adherence was rated subjectively by the physician only, the results of the OBSEER study should be an accurate reflection of the real-life situation compared with controlled study populations in which adherence is thought to be artificially high \[[@CR1]\]. The long-term consequences of medication non-adherence have not been examined in ADHD, but it is generally believed that maintaining good adherence to treatment regimens will maximise efficacy outcomes. In a review of clinical trial populations of both children and adults, mean non-adherence rates of between 13.2 and 64% were found \[[@CR1]\]. The highest (64%) of these rates was seen 5 years after treatment began, suggesting that non-adherence increases when patients are followed for longer periods of time \[[@CR9]\].

While the study design based on the routine care setting is of clear value to clinical practice, as confirmed by previous 'real-life' studies in ADHD \[[@CR19], [@CR33]\], there were several limitations to this study. As this was a non-randomised, open-label trial without a control group, the raters were not blinded to study treatment or dose. Patients with low QoL on prior medications may be over-represented, as this may have been a motivating factor for study participation, and this may limit the generalisability of the results. In addition, KINDL data are only available for patients aged from 8 years onwards, and not from age 6 years as originally planned.

This study demonstrated that, compared with prior therapy including MPH-MR preparations, once-daily Equasym XL^®^ improves QoL and treatment satisfaction, as assessed by both parents and patients under routine care conditions. ADHD has a major impact on patient QoL, and using treatment options that are accepted by patients may represent an effective strategy to improve QoL. Such observational studies should prompt the further investigation of the benefits of using drug treatment in terms of QoL for patients and their families, and treatment satisfaction in a real-life setting.
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